AR071777A1 - Anticuerpos contra receptor tipo inmunoglobulina de leucocitos (anti-pirb), polinucleotidos que codifican dichos anticuerpos y vectores que comprende los polinucleotidos - Google Patents
Anticuerpos contra receptor tipo inmunoglobulina de leucocitos (anti-pirb), polinucleotidos que codifican dichos anticuerpos y vectores que comprende los polinucleotidosInfo
- Publication number
- AR071777A1 AR071777A1 ARP090101723A ARP090101723A AR071777A1 AR 071777 A1 AR071777 A1 AR 071777A1 AR P090101723 A ARP090101723 A AR P090101723A AR P090101723 A ARP090101723 A AR P090101723A AR 071777 A1 AR071777 A1 AR 071777A1
- Authority
- AR
- Argentina
- Prior art keywords
- polinucleotides
- antibodies
- pirb
- leucocits
- immunoglobuline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente se refiere generalmente al desarrollo neural y trastornos neurologicos. Se trata espec¡ficamente de nuevos moduladores del sistema inhibidor asociado con mielina y varios usos de los moduladores identificados de este modo. Los anticuerpos anti-PirB promueven la regeneracion de axones, por lo cual son utiles para tratar una enfermedad neurodegenerativa que se caracteriza por dano f¡sico del SNC.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5294908P | 2008-05-13 | 2008-05-13 | |
US12/208,883 US20100047232A1 (en) | 2006-11-14 | 2008-09-11 | Modulators of neuronal regeneration |
US12/316,130 US20090232794A1 (en) | 2007-12-11 | 2008-12-09 | Modulators of neuronal regeneration |
Publications (1)
Publication Number | Publication Date |
---|---|
AR071777A1 true AR071777A1 (es) | 2010-07-14 |
Family
ID=41319035
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090101723A AR071777A1 (es) | 2008-05-13 | 2009-05-13 | Anticuerpos contra receptor tipo inmunoglobulina de leucocitos (anti-pirb), polinucleotidos que codifican dichos anticuerpos y vectores que comprende los polinucleotidos |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP2291405A1 (es) |
JP (1) | JP2011523359A (es) |
KR (1) | KR20110011676A (es) |
CN (1) | CN102089327A (es) |
AR (1) | AR071777A1 (es) |
AU (1) | AU2009246443A1 (es) |
BR (1) | BRPI0912769A2 (es) |
CA (1) | CA2723430A1 (es) |
IL (1) | IL209129A0 (es) |
MX (1) | MX2010012299A (es) |
PE (1) | PE20091969A1 (es) |
RU (1) | RU2010150754A (es) |
TW (1) | TW200950808A (es) |
WO (1) | WO2009140361A1 (es) |
ZA (1) | ZA201007976B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2787783A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Anti-ilt5 antibodies and ilt5-binding antibody fragments |
WO2011091181A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
JP6162219B2 (ja) * | 2012-04-17 | 2017-07-12 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | 脳卒中および虚血または虚血状態において使用するためのヒト抗体およびその特異的結合配列 |
CN103130898B (zh) * | 2013-01-28 | 2014-03-26 | 中国人民解放军第四军医大学 | Tat-lbd-pep融合蛋白及其在治疗中枢神经系统损伤疾病中的应用 |
EP3728318A2 (en) | 2017-12-22 | 2020-10-28 | Jounce Therapeutics, Inc. | Antibodies for lilrb2 |
MX2021000009A (es) | 2018-07-09 | 2021-03-09 | Five Prime Therapeutics Inc | Anticuerpos de union a transcripcion tipo inmunoglobulina 4 (ilt4). |
CN109439661B (zh) * | 2018-10-22 | 2020-10-23 | 西安医学院 | 抑制pirB表达的短发卡shRNA、慢病毒及其应用 |
WO2021222544A1 (en) | 2020-05-01 | 2021-11-04 | Ngm Biopharmaceuticals, Inc. | Ilt-binding agents and methods of use thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1453540A4 (en) * | 2001-11-14 | 2005-06-01 | Immunex Corp | MODULATION OF THE LIR FUNCTION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
EP1981522B1 (en) * | 2006-01-23 | 2012-09-12 | President and Fellows of Harvard College | Compositions and methods for enhancing neuronal plasticity and regeneration |
-
2009
- 2009-05-13 AR ARP090101723A patent/AR071777A1/es not_active Application Discontinuation
- 2009-05-13 BR BRPI0912769A patent/BRPI0912769A2/pt not_active IP Right Cessation
- 2009-05-13 KR KR1020107027786A patent/KR20110011676A/ko not_active Application Discontinuation
- 2009-05-13 TW TW098115945A patent/TW200950808A/zh unknown
- 2009-05-13 PE PE2009000673A patent/PE20091969A1/es not_active Application Discontinuation
- 2009-05-13 RU RU2010150754/10A patent/RU2010150754A/ru not_active Application Discontinuation
- 2009-05-13 EP EP09747445A patent/EP2291405A1/en not_active Withdrawn
- 2009-05-13 CA CA2723430A patent/CA2723430A1/en not_active Abandoned
- 2009-05-13 MX MX2010012299A patent/MX2010012299A/es active IP Right Grant
- 2009-05-13 AU AU2009246443A patent/AU2009246443A1/en not_active Abandoned
- 2009-05-13 WO PCT/US2009/043757 patent/WO2009140361A1/en active Application Filing
- 2009-05-13 CN CN2009801265242A patent/CN102089327A/zh active Pending
- 2009-05-13 JP JP2011509642A patent/JP2011523359A/ja active Pending
-
2010
- 2010-11-04 IL IL209129A patent/IL209129A0/en unknown
- 2010-11-08 ZA ZA2010/07976A patent/ZA201007976B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2009140361A1 (en) | 2009-11-19 |
ZA201007976B (en) | 2012-02-29 |
EP2291405A1 (en) | 2011-03-09 |
RU2010150754A (ru) | 2012-06-20 |
KR20110011676A (ko) | 2011-02-08 |
BRPI0912769A2 (pt) | 2015-10-13 |
CA2723430A1 (en) | 2009-11-19 |
CN102089327A (zh) | 2011-06-08 |
JP2011523359A (ja) | 2011-08-11 |
MX2010012299A (es) | 2010-12-06 |
PE20091969A1 (es) | 2010-01-15 |
IL209129A0 (en) | 2011-01-31 |
TW200950808A (en) | 2009-12-16 |
AU2009246443A1 (en) | 2009-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR071777A1 (es) | Anticuerpos contra receptor tipo inmunoglobulina de leucocitos (anti-pirb), polinucleotidos que codifican dichos anticuerpos y vectores que comprende los polinucleotidos | |
UA113397C2 (xx) | Попередження несприятливих ефектів, спричинених специфічними доменами зв'язування cd3 | |
CL2018003821A1 (es) | Compuestos de indol sustituidos con (1,2,4)triazolo(1,5-a)piridinilo. | |
UY32449A (es) | Benzazepinas fusionadas como ligandos de receptor de acetilcolina nicotínico neuronal | |
CL2014001212A1 (es) | Compuestos heterobiciclicos condensados, inhibidores de fosfodiesterasa tipo 10a; composicion farmaceutica que los comprende; y metodo para tratar un trastorno seleccionado entre trastornos neurologicos y trastornos psiquiatricos. | |
MX2016005017A (es) | Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2. | |
CO6480999A2 (es) | Metodos para aumentar los adipocitos termogenicos | |
EA201000673A1 (ru) | СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ | |
WO2012149478A3 (en) | Agents useful for treating friedreich's ataxia and other neurodegenerative diseases | |
MX2011012597A (es) | Nanoportadores que poseen componentes con diferentes tasas de liberacion. | |
MX351824B (es) | Sistema y método para recompensar a los viajeros diarios. | |
UY30080A1 (es) | Compuestos de heteroarilo biciclicos como inhibidores de pde10 | |
PE20210949A1 (es) | Anticuerpos anti-fgfr2iiib afucosilados | |
CR11868A (es) | Antagonistas especificos del receptor fgf-r4 | |
SV2009003349A (es) | Compuestos triciclicos, composiciones y procedimientos | |
BR112013027500A2 (pt) | liberação controlada de imunossupressores de nanotransportadores sintéticos | |
EA201490029A1 (ru) | Соединения, ингибирующие металлоферменты | |
EA201590173A1 (ru) | Иммуноконъюгаты, содержащие антитела к cd22 | |
MX2012001052A (es) | Proteccion del cable de fibra optica en un sistema de extraccion. | |
UY33665A (es) | Derivado peptídico | |
FR2972176B1 (fr) | Architectures de freinage hydraulique pour aeronef permettant de freiner au moins une roue de l'aeronef. | |
ECSP12012023A (es) | 3,6-diazabiciclo [3.1.1] heptanos como ligandos de receptores nicotínicos neuronales de acetilcolina | |
GT200600422A (es) | Derivados de carboxamida como antagonistas del receptor muscarinico | |
AR100978A1 (es) | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS | |
CR20150496A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |